Recombinant Anti-HER2 x Anti-VEGF Bispecific Antibody (VHH-IgG) is formed by an IgG and two VHH fragments. The VHHs from an anti-VEGF antibody variable domain are respectively connected to the N terminus of the anti-HER2 IgG heavy chains or light chains to form VHH-(H)IgG or VHH-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can bind two factors simultaneously and inhibit cell proliferation. It is designed for the research of Colorectal cancer; Breast cancer; Lung cancer; Renal cell cancer (RCC); Glioma cancer; Glioblastoma; Ovarian cancer therapy.